LYNN FRAZIER: Open Payments
NPI 1619918505 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$31,775 in 129 payments from 13 companies in 2025. Trend: 2023 $14,211 · 2024 $23,760 · 2025 $31,775
Speaker / faculty: $20,198Travel & lodging: $8,234Food & beverage: $3,342
| Company | Payments | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 27 | $15,112 |
| Madrigal Pharmaceuticals | 31 | $9,128 |
| Gilead Sciences, Inc. | 30 | $6,565 |
| Janssen Scientific Affairs, LLC | 2 | $195 |
| ViiV Healthcare Company | 17 | $176 |
| Mirum Pharmaceuticals, Inc. | 1 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $118 |
| Novo Nordisk Inc | 5 | $106 |
| ABBVIE INC. | 4 | $94 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
Products named: IQIRVO, REZDIFFRA, Livdelzi, Epclusa, TREMFYA, Livmarli, XIFAXAN, DOVATO.
Industry payments across AR — which companies pay providers there.
